944407-20-9Relevant academic research and scientific papers
Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases
Miles, Timothy J.,Hennessy, Alan J.,Bax, Ben,Brooks, Gerald,Brown, Barry S.,Brown, Pamela,Cailleau, Nathalie,Chen, Dongzhao,Dabbs, Steven,Davies, David T.,Esken, Joel M.,Giordano, Ilaria,Hoover, Jennifer L.,Jones, Graham E.,Kusalakumari Sukmar, Senthill K.,Markwell, Roger E.,Minthorn, Elisabeth A.,Rittenhouse, Steve,Gwynn, Michael N.,Pearson, Neil D.
, p. 2464 - 2469 (2016)
During the course of our research on the lead optimisation of the NBTI (Novel Bacterial Type II Topoisomerase Inhibitors) class of antibacterials, we discovered a series of tricyclic compounds that showed good Gram-positive and Gram-negative potency. Herein we will discuss the various subunits that were investigated in this series and report advanced studies on compound 1 (GSK945237) which demonstrates good PK and in vivo efficacy properties.
Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
-
, (2008/12/04)
Tricyclic nitrogen-containing compounds of Formula (I) and pharmaceutically acceptable derivatives thereof: compositions containing them, their use in the treatment of tuberculosis, and methods for the preparation of such compounds.
TRICYCLIC COMPOUNDS AS ANTIBACTERIALS
-
Page/Page column 41, (2008/12/08)
Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.
